drugset
drugset / Trial / NCT03875859

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

NCT03875859 ↗

Phase 2 Terminated 4 enrolled Kavita Sarin Medivir · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.

Timeline

Start
2019-12-12
Primary completion
2020-05-14
Completion
2021-01-30

Outcome

Outcome not reported

Stopped: “The available study medication reached expiry (logistics).”

Drugs

EvaluationDrugModalityDoseRoute
Subject Remetinostat Small molecule 1 % Topical

Indications

squamous cell carcinoma